Ignite Creation Date:
2024-05-05 @ 11:23 PM
Last Modification Date:
2024-10-26 @ 10:33 AM
Study NCT ID:
NCT01320865
Status:
WITHDRAWN
Last Update Posted:
2014-02-04
First Post:
2011-03-18
Brief Title:
Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib
Sponsor:
The Cleveland Clinic
Organization:
The Cleveland Clinic
Study Overview
Official Title:
None
Status:
WITHDRAWN
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators hypothesize that bone marrow progenitor cells are mobilized into the circulation in PAH home to the lungs and differentiate into mast cells which promote vascular remodeling and vasoconstriction through release of renin and chymase As a corollary to this the investigators hypothesize that anti cKit tyrosine kinase inhibitor TKI nilotinib provides clinical benefit to patients through inhibition of mast cell progenitor proliferation mobilization and differentiation To test this the investigators will determine if mast cell progenitors and mast cell biomarkers are related to nilotinib clinical response This will be an ancillary study part of a placebo-controlled double-blind multi center clinical trial of nilotinib in pulmonary arterial hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None